【摘要】：為了探討胞苷脫氨酶(CDA)基因多態(tài)性與晚期非小細胞肺癌(NSCLC)患者含吉西他濱化療療效的關(guān)系。在試驗中120例患者均接受含吉西他濱化療,采用直接測學(xué)法檢測化療前CDA A79C和G208A的基因多態(tài)性,比較不同基因型與療效的關(guān)系。結(jié)果表明CDA G208A位點中,基因型及等位基因與化療有效率的差異無統(tǒng)計學(xué)意義,攜帶突變等位基因的基因型相對于野生型純合子化療無效的風(fēng)險未升高(p=0.768);CDA A79C AA、AC、CC基因型的有效率依次為41.3%、20.0%和6.7%,A、C等位基因的有效率分別為37.8%和13.3%,差異均有統(tǒng)計學(xué)意義(p0.05);以野生型AA型為參照,突變基因型AC和CC化療無效的風(fēng)險均升高,且C等位基因相對于A等位基因化療無效的風(fēng)險也升高,差異均有統(tǒng)計學(xué)意義(p0.05)。CDA A79C多態(tài)性與化療療效有關(guān),且攜帶突變等位基因患者化療無效的風(fēng)險較高,可以為臨床個體化用藥提供參考。
[Abstract]:To investigate the relationship between cytidine deaminase (CDA) gene polymorphism and the efficacy of gemcitabine chemotherapy in patients with advanced non-small cell lung cancer (NSCLC). All 120 patients received gemcitabine chemotherapy. The gene polymorphism of CDA A79C and G208A before chemotherapy was detected by direct assay, and the relationship between different genotypes and curative effect was compared. The results showed that there was no significant difference in the efficacy of chemotherapy between CDA G208A and genotype G208A, but the risk of ineffective chemotherapy with mutant alleles was not higher than that of wild type homozygote (p 鈮，

本文編號：2515366